899821-23-9

Product Details;

CasNo： 899821-23-9

Chinese Manufacturer Supply ACP-105, Buy 899821-23-9 with Safe Delivery

ACP-105 was created to help as a treatment for patients undergoing degenerative bone disorders. It was used for disorders such as arthritis and osteoporosis. The structure of ACP-105 (2-chloro-4-[(3-endo)-3-hydroxy-3-methyl-8-azabicyclo[3.2. 1]oct-8-yl]-3-methylbenzonitrile). Selective Androgen Receptor Modulators (SARMs) have anabolic properties but less adverse effects than anabolic androgenic steroids. Anhui JKN Technology Co., LTD supply ACP-105 899821-23-9 with Safe Delivery.

What does ACP-105 do?

ACP-105 is a drug which acts as a selective androgen receptor modulator (SARM). It has been investigated for the treatment of age-related cognitive decline. ACP-105 binds itself to androgen receptors of the body and minimizes the levels of lipoproteins in the body while helping you build solid muscle mass. This helps you experience overall muscle growth without any damage whatsoever to critical organs such as the liver, prostate, and kidneys.

Scholarly articles about ACP-105 899821-23-9

Detection and identification of ACP-105 and its metabolites in equine urine using LC/MS/MS after oral administration

Michael Benedict Subhahar, Abdul Khader Karakka Kal, Moses Philip, Tajudheen K. Karatt,

Drug Testing and Analysis, Volume13, Issue2 February 2021 Pages 299-317

To obtain the metabolic profile of ACP-105, a selective and reliable LC-MS/MS method was developed. The chemical structures of the metabolites were determined based on their fragmentation pattern, accurate mass, and retention time. Under the current experimental condition, a total of 19 metabolites were detected in ACP-105 drug administered equine urine samples.

In vitro and in vivo profile of a novel tissue selective, orally bioavailable non-steroidal androgen receptor modulator (ACP-105)

Stefania Risso Bradley, Jelveh Lameh, Nathalie Schlienger, Kathy Whitten, Rasmus Lewinsky, Fabrizio Badalassi, Jan Pawlas, Bo-Ragnar Tolf, Douglas Bonhaus, Fabrice Piu

The FASEB Journal, Volume22, IssueS2 Special Issue: Experimental Biology 2008 Meeting Abstracts April 2008 Pages 670-670

We report here the in vitro and in vivo profile of one of these SARMs, named ACP-105. In cell based assays ACP-105 was found to be a potent and selective androgen receptor agonist. Studies using castrated rats demonstrated that ACP-105 potently suppressed the luteinizing hormone surge and had robust anabolic effects on the levator ani muscle.